公开(公告)号：US07279294B2

公开(公告)日：2007-10-09

申请号：US10257021

申请日：2001-04-03

申请人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

发明人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

IPC分类号： G01N33/574

CPC分类号： C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/158

摘要： The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

摘要翻译： 本发明的特征在于通过检测受试者或来自受试者的样品中卵巢肿瘤标志物基因的表达增加来诊断和预测卵巢肿瘤的方法。 还提供了上述诊断和预后方法的试剂盒。 此外，本发明的特征在于通过调节卵巢肿瘤标志物多肽的产生或活性来治疗和预防卵巢肿瘤的方法，以及抑制卵巢肿瘤生长或转移的方法。 进一步特征是通过使卵巢肿瘤细胞与特异性结合卵巢肿瘤标记多肽的抗体接触来抑制卵巢肿瘤的生长或转移的方法。

公开(公告)号：US20080253963A1

公开(公告)日：2008-10-16

申请号：US11895326

申请日：2007-08-24

申请人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

发明人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

IPC分类号： A61K51/10 ,  A61K39/395 ,  A61P35/04

CPC分类号： C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/158

摘要： The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

摘要翻译： 本发明的特征在于通过检测受试者或来自受试者的样品中卵巢肿瘤标志物基因的表达增加来诊断和预测卵巢肿瘤的方法。 还提供了上述诊断和预后方法的试剂盒。 此外，本发明的特征在于通过调节卵巢肿瘤标志物多肽的产生或活性来治疗和预防卵巢肿瘤的方法，以及抑制卵巢肿瘤生长或转移的方法。 进一步特征是通过使卵巢肿瘤细胞与特异性结合卵巢肿瘤标记多肽的抗体接触来抑制卵巢肿瘤的生长或转移的方法。

公开(公告)号：US20100183507A1

公开(公告)日：2010-07-22

申请号：US12700311

申请日：2010-02-04

申请人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

发明人： Patrice J. Morin ,  Cheryl A. Sherman-Baust ,  Ellen S. Pizer ,  Colleen D. Hough

IPC分类号： A61K51/10 ,  G01N33/567 ,  G01N33/53 ,  C12Q1/68 ,  A61K39/395 ,  A61P35/00

CPC分类号： C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/158

摘要： The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

摘要翻译： 本发明的特征在于通过检测受试者或来自受试者的样品中卵巢肿瘤标志物基因的表达增加来诊断和预测卵巢肿瘤的方法。 还提供了上述诊断和预后方法的试剂盒。 此外，本发明的特征在于通过调节卵巢肿瘤标志物多肽的产生或活性来治疗和预防卵巢肿瘤的方法，以及抑制卵巢肿瘤生长或转移的方法。 进一步特征是通过使卵巢肿瘤细胞与特异性结合卵巢肿瘤标记多肽的抗体接触来抑制卵巢肿瘤的生长或转移的方法。

公开(公告)号：US5874235A

公开(公告)日：1999-02-23

申请号：US896462

申请日：1997-07-18

申请人： Timothy A. Chan ,  Patrice J. Morin ,  Bert Vogelstein ,  Kenneth W. Kinzler

发明人： Timothy A. Chan ,  Patrice J. Morin ,  Bert Vogelstein ,  Kenneth W. Kinzler

IPC分类号： G01N33/50 ,  C12Q1/34 ,  C12Q1/00 ,  C12Q1/42

CPC分类号： G01N33/5011

摘要： Nonsteroidal anti-inflammatory drugs cause a dramatic increase in intracellular ceramide, which induces apoptosis. The ceramide increase is likely mediated by cyclooxygenase inhibition, which elevates arachidonic acid, which stimulates sphingomyelinase, which produces ceramide. Contacting members of this pathway with test compounds and observing their effects provides a method of screening for potential cancer chemopreventative agents.

摘要翻译： 非甾体抗炎药引起细胞内神经酰胺的剧烈增加，诱导细胞凋亡。 神经酰胺增加可能由环氧合酶抑制介导，其升高花生四烯酸，其刺激产生神经酰胺的鞘磷脂酶。 将该途径与测试化合物接触并观察其作用提供了筛选潜在的癌症化学预防剂的方法。

公开(公告)号：US5851775A

公开(公告)日：1998-12-22

申请号：US821355

申请日：1997-03-20

申请人： Nick Barker ,  Hans Clevers ,  Kenneth W. Kinzler ,  Vladimer Korinek ,  Patrice J. Morin ,  Andrew B. Sparks ,  Bert Vogelstein

发明人： Nick Barker ,  Hans Clevers ,  Kenneth W. Kinzler ,  Vladimer Korinek ,  Patrice J. Morin ,  Andrew B. Sparks ,  Bert Vogelstein

IPC分类号： G01N33/50 ,  A61K31/711 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/47 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53

CPC分类号： C07K14/47 ,  C07K14/4705 ,  C12Q1/6897 ,  A61K38/00 ,  A61K48/00

摘要： The APC tumor suppressor protein binds to .beta.-catenin, a protein recently shown to interact with Tcf/Lef transcription factors. Here, the gene encoding a Tcf family member that is expressed in colonic epithelium (hTcf-4) was cloned and characterized. hTcf-4 transactivates transcription only when associated with .beta.-catenin. Nuclei of APC.sup.-/- colon carcinoma cells were found to contain a stable .beta.-catenin-hTCF-4 complex that was constitutively active, as measured by transcription of a Tcf reporter gene. Reintroduction of APC removed .beta.-catenin from hTcf4 and abrogated the transcriptional transactivation. Constitutive transcription of TCF target genes, caused by loss of APC function, may be a crucial event in the early transformation of colonic epithelium. It is also shown here that the products of mutant APC genes found in colorectal tumors are defective in regulating .beta.-catenin/Tcf-4 transcrpitional activation. Furthermore, colorectal tumors with intact APC genes were shown to contain subtle activating mutations of .beta.-catenin that altered functionally significant phosphorylation sites. These results indicate that regulation of .beta.-catenin is critical to APC's tumor suppressive effect and that this regulation can be circumvented by mutations in either APC or .beta.-catenin.

摘要翻译： APC肿瘤抑制蛋白结合β-连环蛋白，最近显示出与Tcf / Lef转录因子相互作用的蛋白质。 这里，克隆并表征编码在结肠上皮（hTcf-4）中表达的Tcf家族成员的基因。 hTcf-4仅在与β-连环蛋白相关时才转录转录。 发现APC - / - 结肠癌细胞的核含有稳定的β-联蛋白-hTCF-4复合物，其通过Tcf报道基因的转录测量而具有组成型活性。 重新引入APC从hTcf4中除去β-连环蛋白，并废除转录反式激活。 由APC功能丧失引起的TCF靶基因的组成转录可能是结肠上皮早期转化的关键事件。 这里还显示，在结肠直肠肿瘤中发现的突变APC基因的产物在调节β-连环蛋白/ Tcf-4跨刺激激活中是有缺陷的。 此外，具有完整APC基因的结肠直肠肿瘤显示含有改变功能显着磷酸化位点的β-连环蛋白的微妙活化突变。 这些结果表明，β-连环蛋白的调节对于APC的肿瘤抑制作用至关重要，并且该调节可以通过APC或β-连环蛋白的突变来规避。